Clinical trials: Eye
Choroidal Melanoma, Indeterminate Lesions
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
- Conditions
- Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
- Trial name
- CoMpass (NCT06007690)
- Testing
- Bel-sar, Suprachoroidal Microinjector, Infrared Laser
- Where
- 53 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Aura Biosciences
Acne
Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic Subjects
The aim of this study is firstly to assess the tolerance of the sunscreen RV4857A-CD2110 after 28 days and 57 days of at least a twice daily on the study areas, secondly to assess anti-imperfection efficacy after 28 days and 57…
- Trial name
- NCT05168397
- Testing
- RV4857A
- Where
- Portugal
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Age-Related Macular Degeneration
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months.
- Trial name
- RIVAL (NCT02130024)
- Testing
- Ranibizumab 0.5 mg, Aflibercept 2.0 mg
- Where
- 22 sites in Australia
- Volunteers
- 281 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Refractive Errors, Myopia
Performance Assessment of a Modified Daily Disposable Contact Lens
The purpose of this study is to compare visual acuity between two daily disposable contact lenses.
- Conditions
- Refractive Errors, Myopia, Hyperopia
- Trial name
- NCT03762668
- Testing
- Modified delefilcon A contact lenses, Delefilcon A contact lenses
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Alcon Research
Healthy Volunteers and Glaucoma Patients
Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients
To assess the safety and tolerability of repeat dose topical administration of MRZ-99030 Ophthalmic Solution with ascending doses in healthy subjects (stage 1) and glaucoma subjects (stage 2).
- Trial name
- NCT01714960
- Testing
- MRZ-99030 eye drops 5mg/mL, MRZ-99030 eye drops 20mg/mL
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Merz Pharmaceuticals GmbH
Keratoconjunctival Epithelial Disorder
Exploratory Study of OPC-12759 Ophthalmic Suspension
The purpose of this study is to evaluate the efficacy of OPC-12759 ophthalmic suspension for patients with keratoconjunctival epithelial disorder compared with sodium hyaluronate. Also, safety of OPC-12759 is to be assessed.
- Trial name
- NCT01493180
- Testing
- OPC-12759 ophthalmic suspension, Sodium hyaluronate ophthalmic solution
- Where
- 10 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Cornea
Evaluation of the Accuracy of Corneal Epithelial Thickness Mapping With SD-OCT
Evaluate the accuracy of the RTVue-XR and iVue for measuring the total corneal thickness, the epithelial thickness, and the stromal thickness in normal subjects and patients with various corneal conditions.
- Trial name
- NCT02775097
- Testing
- OCT
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Optovue
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- GOBI (NCT07842016)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Glaucoma, Open Angle Glaucoma
Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-SC system.
- Trial name
- NCT04773106
- Testing
- ARGOS-SC suprachoroidal pressure sensor
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 22 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Healthy Volunteer
PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects
An open label, multiple-dose, phase 1 clinical trial to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of PHP-201 topical eye drop in Korean and Japanese healthy subjects
- Trial name
- NCT03586908
- Testing
- PHP-201 0.5% ophthalmic solution (topical eye drop)
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- pH Pharma
Dry Eye Disease
Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome
The study is designed to assess the safety and efficacy of Vismed®, a special eye drop containing sodium hyaluronate, in the treatment of dry eye syndrome.
- Trial name
- NCT00599716
- Testing
- sodium hyaluronate, vehicle
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Lantibio
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "Ocular Drops Based Upon Carmellose" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by symptoms such as ocular discomfort and…
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05825352
- Testing
- Carmellose eye drops
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Age-related Cataract, Vision Loss
Long-term Safety & Performance of REVISYON SDS100 in Mild to Moderate Cataract: Extension Study (EB-CE-02)
A non-interventional, extension study on the long-term maintenance of safety and performance of the REVISYON SDS 100 medical device in subjects with mild-to-moderate cataract.
- Conditions
- Age-related Cataract, Vision Loss, Cataract, Mild Cataract
- Trial name
- EB-CE-02 (NCT07246915)
- Where
- 6 sites in Romania
- Volunteers
- 47 people
- Sponsor
- Edinburgh Biosciences Ltd
Age-related Macular Degeneration
Genetic Load and Phenotype in Aggressive AMD
Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
- Trial name
- RPED Genetics (NCT01650948)
- Testing
- RetnaGene AMD LDT
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sequenom, Inc.
Glaucoma
A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage
Open-angle glaucoma is the most common type of glaucoma, a disease that damages the nerves in the eye and can lead to vision loss. Current treatments include eye drops, laser treatment, and surgery that help lower eye pressure.
- Trial name
- NCT07770685
- Testing
- ASP2767, Prophylactic Regimen A, Prophylactic Regimen B
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Dry Eye Syndromes
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
The purpose of this study is to evaluate if, in patients with meibomian gland dysfunction (MGD), treatment with the Lumenis M22 Intense Pulsed Light (IPL) system causes a reduction in dry eye symptoms post-treatment, compared to…
- Trial name
- NCT02621593
- Testing
- M22-IPL
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Lumenis Be Ltd.
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Dry Eye Disease
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects
Dry eye disease (DED) is a keratoconjunctive disorder that "is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage…
- Trial name
- NCT04762355
- Testing
- Palovarotene, Vehicle
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Clementia Pharmaceuticals Inc.
Primary Open Angle Glaucoma, Intraocular Pressure
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients.
- Trial name
- NCT00864578
- Where
- Italy
- Sponsor
- Sooft Italia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.